Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Duffy

Orthopaedic Surgery Stratford, NJ Doctor of Osteopathy

NPI 1447221692 CMS profile 292574

42 Laurel Road, Ste 1200, Stratford, NJ 08084

Open in the dashboard

General payments

$876

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Duffy of Stratford, NJ is reported in the CMS Open Payments database as having received $876 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 28th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54 3
2024 General $415 4
2023 General $21 1
2022 General $257 12
2021 General $30 2
2019 General $100 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Duffy
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Duffy were reported at $54. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Duffy Orthopaedic Surgery median Middle half National median
2019 $100 $644 $140–$2,844 $163
2020 $0 $312 $75–$1,860 $114
2021 $30 $520 $117–$2,495 $132
2022 $257 $598 $128–$2,731 $149
2023 $21 $461 $128–$2,264 $160
2024 $415 $497 $134–$2,475 $164
2025 $54 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eclipse Technology Solutions Inc. $299 2 payments
  2. Djo, LLC $253 13 payments
  3. Stryker Corporation $211 6 payments
  4. Radius Health, Inc. $56 3 payments
  5. Avanos Medical $22 1 payment
  6. Heraeus Medical, LLC. $21 1 payment
  7. Kowa Pharmaceuticals America, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $653 16 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $222 11 payments
Products named General payments · program years 2019–2025
  1. PROCARE $234 12 payments
  2. VARIAX $75 1 payment
  3. AXSOS $62 2 payments
  4. Tymlos $56 3 payments
  5. TRIATHLON $39 1 payment
  6. ON-Q* PUMP AND ACCESSORIES $22 1 payment
  7. ASNIS $21 1 payment
  8. PALACOS $21 1 payment
  9. DONJOY $19 1 payment
  10. Seglentis $14 1 payment
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

474

Median for Orthopedic Surgery: 203

Drug cost

$5,167

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 24 $1,832
Lidocaine Generic 11 $751
Oxycodone Hcl Generic 67 $526
Meloxicam Generic 132 $405
Ibuprofen Generic 43 $358
Tramadol Hcl Generic 34 $335
Tizanidine Hcl Generic 54 $300
Celecoxib Generic 13 $215
Naproxen Generic 19 $139
Gabapentin Generic 11 $117

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$53,854

Of which drugs: $2,273

Medicare patients

219

Average age 71

Services billed

6,817

148 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 44%
Ischemic heart disease 31%
Depression 29%
Chronic kidney disease 25%
Heart failure 23%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 37 6,242 $644
Injection, methylprednisolone acetate, 80 mg J1040 Office 18 28 $191

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record